Aims To compare the absorption and clinical effect of spironolactone from an inclusion complex with b-cyclodextrin (SP-COMP) to Aldactone tablets (ALD) in chronic liver disease. Methods Patients, admitted with chronic liver disease, completed a randomized crossover steady state study. They received their spironolactone dose as either daily SP-COMP or ALD for 7 days. Serial blood samples were drawn over a 24 h period from day 7 of each therapy. Accurate fluid balance was recorded on days 5-7 and 12-14. Thirteen (six females) whose mean (s.d.) age and weight was 58.4(9.3) years and 74.3(19.0) kg completed the study. Results The mean (95% confidence limits) relative bioavailability for SP-COMP (compared with ALD) from steady state serum concentrations of canrenone, 6b-hydroxyl 7a-thiomethyl spironolactone and 7a-thiomethyl spironolactone was 310.0 (265.4, 336.7), 233.4(212.9, 250.8) and 254.8(230.8, 279.0)%, respectively. Improvements in clinical status and fluid balance occurred over the last 3 days of SP-COMP with a mean (s.d.) net loss, in fluid balance, of 1370(860)ml compared with a gain of 228(936)ml during ALD. Conclusions Better absorption of spironolactone from the spironolactone: b-cyclodextrin complex formulation should lead to a reduction in dosage and perhaps a more consistent effect in patients with chronic liver disease.
Introduction cavity into which a drug can be incorporated. They are formed by the action of the bacterial enzyme cycloglycosyl Spironolactone is a steroidal aldosterone antagonist that has been widely used for almost 30 years in disorders associated transferase (e.g. Bacillus macerans, Klebsiella pneumoniae) on starch [6] . The formation of a, b and c-cyclodextrin is with primary or secondary hyperaldosteronism. At present it is mainly used as a diuretic to control ascites in chronic dependent on the bacterial source of the enzyme [7] . Inclusion complexation of spironolactone with liver disease. It has a low and erratic bioavailability due to poor aqueous solubility which restricts its dissolution rate b-cyclodextrin [8] [9] [10] [11] and c-cyclodextrin [7] has been reported. [1] . This leads to fluctuating clinical control in compliant patients thereby complicating their management [2, 3] .
The first report of an enhanced bioavailability for spironolactone complexes with b and c-cyclodextrin was Different formulations have been used to improve the spironolactone oral bioavailability using simultaneous adminfollowing oral administration to dogs [10] . There was a 2-3 fold increase in the serum canrenone concentrations at istration of a surface active agent, polysorbate 80 [4] , and by reduction of the particle size [3, 5] . Bioavailability studies 90 min post spironolactone complex dose compared with spironolactone. When an inclusion complex of spironolacusing micronised spironolactone compared with Aldactone tablets (Searle Pharmaceuticals, USA) in healthy volunteers tone with b-cyclodextrin was orally administered to rats there was an increase in their urinary volume compared have revealed a higher C max and large AUC (area under the curve) for the micronised product with a 14% increase in with either spironolactone or b-cyclodextrin alone [9] . The first bioavailability study of a spironolactone: b-cyclodextrin the oral relative bioavailability.
Recently, attention has centred on the formation of complex in humans revealed that significantly higher quantities of fluorimetrically measured canrenone were inclusion complexes of spironolactone with cyclodextrins. a, b and c-cyclodextrin contain six, seven and eight glucose excreted in the urine after oral administration of the complex than after spironolactone [12] . Using a single dose crossover units, respectively, in a ring formation which has a design study in volunteers we have measured serum the AUC) of a spironolactone: b-cyclodextrin complex was 252.0(19.6)% compared with Aldactone 100 mg tablets [13] . by high performance liquid chromatography (h.p.l.c.) with solid phase extraction. We have now extended our bioavailability studies with the administration of spironolactone: b-cyclodextrin complex to Bond Elut 100 mg C18 columns ( Jones Chromatography, UK) were conditioned using 1ml methanol followed by 1ml patients admitted to hospital with chronic liver disease.
water. Serum (1ml) was placed on the column with 0.3 ml megesterol acetate (10 mg ml −1 )-the internal standardMethods and drawn through the column for 3 min using a Vac Elut vacuum system ( Jones Chromatography, UK). Columns Preparation of the spironolactone: b-cyclodextrin complex were washed with 1ml water and dried for 3 min by the (SP-COMP) application of a vacuum. The spironolactone metabolites were then eluted from the column using 1ml methanol. The SP-COMP was formulated as a 154 ratio of spironolactone: b-cyclodextrin. In vitro studies showed that there was This final elute was evaporated to dryness under a gentle steam of nitrogen and the residual analytes were reconstituted an eight fold increase in the aqueous solubility of spironolactone for the SP-COMP compared with spironolactone.
in 0.3ml of (the h.p.l.c.) mobile phase prior to injection. The stationary phase of the h.p.l.c. system was a 4.6 mm Capsules containing 125 mg of SP-COMP (equivalent to 25 mg spironolactone) were manufactured. Dissolution (internal diameter)×15cm Spherisorb C18 column with a 2cm Spherisorb C18 pre-column ( Jones Chromatography, studies using simulated gastric fluid (US Pharmacopoeia Monograph for spironolactone tablets) revealed that after UK). The mobile phase was 65% methanol in water at a flow rate of 1.0 min −1 . A Gilson UV model 116 dual 30 min 99.6(±2.84)% of the spironolactone had dissolved compared with 47.8(±2.76)% for Aldactone tablets (n=10).
detector (Anachem, UK) was set at 240nm for the detection of spironolactone, 7a-methyl spironolactone and 6b-hydroxy 7a-thiomethyl spironolactone and at 280nm for canrenone Patients and samples and megesterol acetate. Reconstituted sample (100 ml) was injected into the system for each assay. Ethics committee approval was obtained from St James's University Hospital, Leeds (UK). Patients admitted with chronic liver disease who gave written informed consent
Analysis of the data were recruited into the study. The patients had chronic liver disease secondary to either primary biliary cirrhosis,
The AUC at steady state was calculated using the linear trapezoid rule between the serum concentrations of the chronic alcohol intake or chronic active hepatitis. Their medication on admission included spironolactone. Those blood samples taken before the study dose (t=0) and at t= 24 h (immediately before the next morning's dose). C max whose management plan was to maintain the drug therapy of admission with daily monitoring continued the study, was taken to be the highest serum concentration of the blood samples and the time of this occurrence was the t max . otherwise they were excluded. They were randomized to receive their daily (morning ) dose of spironolactone at Half-lives were not calculated from the terminal slope of the serum concentration data because of the lack of a 06.00 h (before breakfast) as either the spironolactone: b-cyclodextrin capsules (SP-COMP) containing the equivalsufficient number of samples in the terminal phase. Statistical comparisons of the AUC, C max and t max data ent of 25 mg spironolactone, or Aldactone 100 mg tablets (ALD). After 7 days of continuous drug therapy blood were made by the Wilcoxon signed rank test and the median difference with their 95% confidence intervals were samples were drawn via an in-dwelling heparinised cannula, at 0, 0.5, 1, 2, 4, 8, 12, 16 and 24 h post dose. The patients calculated. For each metabolite profile the serum concentration at t=0 was compared with that at t=24 h using a were then crossed over to the other preparation and after a further 7 days of constant oral therapy blood samples were paired t-test to demonstrate steady state status. drawn as before. All blood samples were allowed to clot, centrifuged and the serum was separated and stored at Results −20°C until the time of analysis. Serum spironolactone concentrations were undetected in nine of the patients during dosing with Aldactone tablets. Figures 1a, b and c show that the serum concentrations of CAN, 6-OH and 7-TH, respectively, were greater during the administration of SP-COMP than ALD. Statistical analysis ( paired t-test) between the serum metabolite concentration for each profile at t=0 and t=24 h after the administration of each formulation revealed no significant difference. Table 2 shows that the AUC and C max of CAN, 6-OH and 7-TH were significantly greater during the administration of SP-COMP than ALD. The mean (s.d.) relative bioavailability of the SP-COMP (compared with ALD) using the AUC data for CAN, 6-OH and 7-TH was 301.0 (58.9), 233.4(35.2) and 254.8(39.9)%, respectively. The 95% confidence limits of these ratios was 265.4-336.7, 212.9-250.8 and 230.8-279.0. Analysis of variance demonstrated that there were no period effects nor treatmentperiod interactions.
Following daily clinical examination, all patients were noted to have improved on day 7 of SP-COMP therapy but not ALD. Figure 2 shows that this is demonstrated by a marked diuresis in most patients during the last 3 days of SP-COMP administration. The mean (s.d.) fluid balance over the last 3 days of SP-COMP and ALD therapy was −1370 (860) and +228 (936)ml respectively (P<0.001). 7a-thiomethyl spironolactone of 16.5(6.3), 15.0 (4.0) and 13.8(6.5) h have been reported [14] . Other reports of the half-life for canrenone have ranged from 3.9 h [15] to 34.9 h the profiles were measured. Food has been shown to enhance the oral bioavailability of spironolactone [17, 18] [16]. However, these reports are from healthy individuals. Linear regression of all terminal profiles (using the four and so all the spironolactone doses were given in the morning (shortly after waking) at least 1 h before breakfast. samples at t=8, 12, 16 and 24 h post dose) revealed halflives of less than 30 h. These values are not reported because It has been proposed that differences in the absorption of spironolactone tablets are due to the dissolution rate [19] . of the lack of data over a period greater than two half-lives. A washout period of 7 days should, therefore, have been Since the spironolactone: b-cyclodextrin complex capsules demonstrated faster in vitro dissolution characteristics and adequate for the attainment of steady state conditions when improved aqueous solubility then, as expected, the absorption and clinical examination. The overall mean (s.d.) fluid loss for the last 3 days of spironolactone: b-cyclodextrin therapy was better. The area under the curve, used for these values, represents the fraction of the absorbed dose converted to was −1370(860)ml whereas during Aldactone therapy there was a net gain of 228(930)ml for the same period. Values each metabolite and their clearance. It is possible that in addition to inter-subject variability, due to differences in over the last 3 days have been used to allow sufficient time for all the spironolactone and its metabolites to be removed fractions metabolized and clearance, that there could be an intra subject variability related to the spironolactone dose from the body from the previous formulation and because it takes 3-4 days for spironolactone to exert its diuretic swallowed or to improvements in clinical status. Clinical evaluation and the marked diuresis during the administration effect. In clinical practice the use of a spironolactone: b-cyclodextrin formulation should allow a smaller dose of of the spironolactone: b-cyclodextrin therapy indicated that the health of these patients on this therapy improved. The spironolactone to be given. The higher and more consistent absorption should enable patients to be managed more easily decrease in ascitic fluid might have been associated with improved conditions for gastro-intestinal absorption and with a shorter period to stabilization and hence bed-stay may be decreased. However there is a formulation problem reduced hepatic congestion thereby improving metabolic processes. This could help to explain the difference in because the largest manageable capsules for patients contain the equivalent of only 25 mg spironolactone. Thus during relative bioavailability for the three metabolites. Clinical status may also be the reason why the relative bioavailability this study one patient required 16 capsules to receive a 400 mg dose. Studies are in progress to formulate a higher for the spironolactone: b-cyclodextrin complex in these patients for the canrenone metabolites (301%) is greater than dose tablet preparation which will shortly be used in further bioavailability studies. that (252%) which we have previously reported in healthy volunteers [12] .
The clinical benefit gained from improving spironolactone We thank the staff of the Manufacturing and Quality Control Unit of the Pharmacy Department, St James's bioavailability following administration of the spironolactone: b-cyclodextrin complex is demonstrated by the fluid balance University Hospital, Leeds for the manufacture of spironolac-solubility and bioavailability of spironolactone by inclusion in tone : b-cyclodextrin capsules to approved specification. We 
